Cost per Response Analysis of Deucravacitinib and Biologic Treatments for Moderate to Severe Plaque Psoriasis From the Perspective of the Brazilian Private Healthcare System
Author(s)
Paulo Antonio Oldani, MsC1, Daniela A. Mirandola, PhD2, Natalia O. Ribeiro, -2, Leandro L. Alves, PhD2;
1Hospital Federal dos Servidores do Estado RJ, Rio de Janeiro, Brazil, 2Bristol Myers Squibb, São Paulo, Brazil
1Hospital Federal dos Servidores do Estado RJ, Rio de Janeiro, Brazil, 2Bristol Myers Squibb, São Paulo, Brazil
Presentation Documents
OBJECTIVES: Psoriasis is a chronic, inflammatory skin disease affecting both genders, with plaque psoriasis being the most common form. While biologic drugs are available in the Brazilian private setting, there remain realities of disease treatment and their associated financial burdens for patients and the healthcare system, such as parenteral administration, immunogenicity, adverse effects, loss of efficacy, and cold chain costs. The introduction of deucravacitinib, a new advanced oral drug, on the psoriasis care pathway can help address these challenges by providing a different administration route and reducing costs with logistics and administration. This study aims to evaluate the cost-per-response of deucravacitinib and biologic agents recommended in the 2024 Brazilian Psoriasis Consensus.
METHODS: A cost-per-response analysis was conducted to assess the cost per outcome of Psoriasis Area and Severity Index (PASI) 75 and PASI90. Results were presented for the first year (52 weeks) of treatment and based on the probability of response assessed by the Armstrong, et al. 2023 metanalysis. Treatments costs were calculated based on the official list prices published by the Brazilian Price Chamber in November 2024.
RESULTS: The PASI75 cost-per-response were (in BRL): 82,942 (deucravacitinib); 111,349 (brodalumab); 120,633 (guselkumab); 123,887 (risankizumab); 124,741 (bimekizumab); 124,791 (ustekinumab); 144,095 (ixekizumab); 188,579 (secukinumab); 238,727 (adalimumab); 240,311 (etanercept); 271,355 (infliximab). For the PASI90 outcome, the results were: 120,927 (deucravacitinib); 121,226 (brodalumab); 137,386 (risankizumab); 138,529 (bimekizumab); 138,997 (guselkumab); 166,294 (ixekizumab); 168,036 (ustekinumab); 236,107 (secukinumab); 355,514 (adalimumab); 386,578 (infliximab); 398,060 (etanercept).
CONCLUSIONS: Deucravacitinib presented the lowest cost-per-response ratio amongst all treatments available for moderate to severe plaque psoriasis in the Brazilian private
METHODS: A cost-per-response analysis was conducted to assess the cost per outcome of Psoriasis Area and Severity Index (PASI) 75 and PASI90. Results were presented for the first year (52 weeks) of treatment and based on the probability of response assessed by the Armstrong, et al. 2023 metanalysis. Treatments costs were calculated based on the official list prices published by the Brazilian Price Chamber in November 2024.
RESULTS: The PASI75 cost-per-response were (in BRL): 82,942 (deucravacitinib); 111,349 (brodalumab); 120,633 (guselkumab); 123,887 (risankizumab); 124,741 (bimekizumab); 124,791 (ustekinumab); 144,095 (ixekizumab); 188,579 (secukinumab); 238,727 (adalimumab); 240,311 (etanercept); 271,355 (infliximab). For the PASI90 outcome, the results were: 120,927 (deucravacitinib); 121,226 (brodalumab); 137,386 (risankizumab); 138,529 (bimekizumab); 138,997 (guselkumab); 166,294 (ixekizumab); 168,036 (ustekinumab); 236,107 (secukinumab); 355,514 (adalimumab); 386,578 (infliximab); 398,060 (etanercept).
CONCLUSIONS: Deucravacitinib presented the lowest cost-per-response ratio amongst all treatments available for moderate to severe plaque psoriasis in the Brazilian private
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
EE165
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
SDC: Sensory System Disorders (Ear, Eye, Dental, Skin), SDC: Systemic Disorders/Conditions (Anesthesia, Auto-Immune Disorders (n.e.c.), Hematological Disorders (non-oncologic), Pain)